ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:30 AM PT. The presentation will contain a business overview and pipeline update following Millendo’s recent acquisition of Alizé Pharma SAS and subsequent expansion into Prader-Willi syndrome.
About Millendo Therapeutics, Inc.
Millendo Therapeutics is
focused on developing novel treatments for endocrine diseases. Our
mission is to build a leading endocrine company that creates distinct
and transformative treatments for a wide range of diseases where there
is a significant unmet medical need. We are currently advancing
livoletide for the treatment of Prader-Willi syndrome and nevanimibe for
the treatment of classic congenital adrenal hyperplasia and endogenous
Cushing’s syndrome. www.millendo.com